$CRDF News
Last published 1w ago
- 1w agoCRDFCardiff Oncology to Participate in the UBS Global Biopharma ConferenceGlobeNewswireSAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today
- 2w agoCRDFCardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical OfficerGlobeNewswireSAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced the appointment of
- 3w agoCRDFCardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic LeukemiaGlobeNewswireSAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S.
- 1mo agoCRDFCardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License AgreementGlobeNewswireSAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached a
- 2mo agoCRDFCardiff Oncology to Participate in September 2026 ConferencesGlobeNewswireSAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today
- 3mo agoCRDFCardiff Oncology Reports Second Quarter 2026 Results and Provides Business UpdateGlobeNewswirePositive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC Following
- 3mo agoCRDFCardiff Oncology Announces $10 Million Registered Direct OfferingGlobeNewswireSAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF) (the "Company"), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today
- 5mo agoCRDFJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - CARDIFF ONCOLOGY INCEarnings Call TranscriptsHi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'm happy to introduce and welcome Mani Mohindra, CEO, and Josh Muntner, CFO of Cardiff. We're doing a fireside chat format. Than
- 5mo agoCRDFCardiff Oncology Conference CallCARDIFF ONCOLOGY INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to the Cardiff Oncology ASCO data presentation conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there w
- 5mo agoCRDFCardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual MeetingGlobeNewswire- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program - - 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a
- 5mo agoCRDFCardiff Oncology to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireSAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced
- 5mo agoCRDFCardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRCGlobeNewswireSAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it
- 6mo agoCRDFCardiff Oncology Reports First Quarter 2026 Results and Provides Business UpdateGlobeNewswireCompleted successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004 trial in rapid
- 6mo agoCRDFCardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,
- 6mo agoCRDFCardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib's Promising Single-Agent ActivityGlobeNewswireSAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today
- 6mo agoCRDFCardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026GlobeNewswireSAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced it will present
- 6mo agoCRDFCardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual MeetingGlobeNewswireSAN DIEGO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, will
- 7mo agoCRDFCardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of GrowthGlobeNewswireBoard member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief Operating Officer SAN
- 7mo agoCRDFTHE EMERGENT TREATMENT LANDSCAPE: FIRST-LINE KRAS AND RAS-MUTANT METASTATIC COLORECTAL CANCERCARDIFF ONCOLOGY INCEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the Cardiff Oncology, Inc. conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-ans
- 8mo agoCRDFCardiff Oncology to Participate in Three Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced
- 8mo agoCRDFCardiff Oncology Reports Full Year 2025 Results and Provides Business UpdateGlobeNewswireReported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and
- 8mo agoCRDFCardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireSAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced
- 9mo agoCRDFCardiff Oncology, Inc. Conference CallCARDIFF ONCOLOGY INCEarnings Call TranscriptsWelcome to the Cardiff Oncology on VASPR data update call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. Please be advised that tod
- 9mo agoCRDFCardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRCGlobeNewswire- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with
- 9mo agoCRDFCTMXCardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical DevelopmentGlobeNewswireSAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced
- 11mo agoAGENCRDFEXELGILD+1GI Cancer Immunotherapy Breakthroughs Signal New Treatment EraGlobeNewswireVANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA approved the first perioperative immunotherapy for early gastric and gastroesophageal junction cancers last
- 11mo agoCRDFCardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025GlobeNewswireSAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced
- 11mo agoCRDFCardiff Oncology to Present at Sidoti's Year-End Virtual Investor ConferenceGlobeNewswireSAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced
- 11mo agoCRDFCardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireSAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced
- 1y agoCRDFCardiff Oncology Reports Third Quarter 2025 Results and Provides Business UpdateGlobeNewswire– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report an update from
- 1y agoCRDFCardiff Oncology to Participate in Two Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced
- 1y agoCRDFCardiff Oncology to Participate in Two Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced
- 1y agoCRDFCardiff Oncology to Participate in Three Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced
- 1y agoCRDFCardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)GlobeNewswire– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose
- 1y agoCRDFCardiff Oncology Reports Second Quarter 2025 Results and Provides Business UpdateGlobeNewswire- Appointed Dr. Roger Sidhu as Chief Medical Officer - - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic
- 1y agoAZNCRDFMBIOONCY+1Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New TherapiesGlobeNewswirePALM BEACH, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to
- 1y agoCRDFCardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRCGlobeNewswire– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold
- 1y agoCRDFCardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025GlobeNewswire– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of onvansertib in
- 1y agoCRDFCardiff Oncology Reports First Quarter 2025 Results and Provides Business UpdateGlobeNewswire- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") - - Expanded intellectual property
- 1y agoCRDFCardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve PatientsGlobeNewswireSAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today
- 1y agoCRDFCardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today
- 1y agoCRDFCardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal CancerGlobeNewswire- Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - SAN DIEGO, April 15, 2025 (GLOBE
- 1y agoONCYEXELCRDFALXO+1Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the ChargePR NewswireAs the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual...
- 1y agoCRDFCardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business UpdateGlobeNewswire- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer ("mCRC") clinical trial (CRDF-004) - - Priced oversubscribed $40 million underwritten
- 1y agoCRDFCardiff Oncology to Present at Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced
- 1y agoCRDFCardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business UpdateGlobeNewswireSAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced
- 1y agoABBVAZNCRDFGSK+1Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic OutlookGlobeNewswirePALM BEACH, Fla., Dec. 26, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the diverse applications of drugs in various breast cancer
- 1y agoONCYCRDFPSNLTEM+1Oncology Advancements Accelerate Amid Rising Early-Onset Cancer DiagnosesPR NewswireUSA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring major...
- 1y agoCRDFCardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct OfferingGlobeNewswireSAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF) ("Cardiff Oncology" or the "Company"), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies
- 1y agoCRDFCardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical TrialGlobeNewswire- Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated 64% ORR in the 30mg onvansertib dose arm versus 33% ORR in the control arm - - In the